A Pfiz­er part­ner wel­comes ex-ADC Ther­a­peu­tics CMO Jay Fein­gold to the team; Amid tough sled­ding, Im­muno­vant choos­es Eli Lil­ly alum as CFO

→ Last week we told you about the CMO re­volv­ing door at ADC Ther­a­peu­tics, as Joseph Ca­mar­do re­placed the de­part­ing Jay Fein­gold. The next op­por­tu­ni­ty for Fein­gold in the CMO slot has opened up at an­ti­body-drug con­ju­gate and mAb de­vel­op­er Pyx­is On­col­o­gy, which has added sev­er­al new ex­ecs and sci­en­tif­ic ad­vi­so­ry board mem­bers in re­cent months, in­clud­ing ex-Im­muno­vant CFO Pamela Yanchik Con­nealy. Be­fore his tenure at ADC, Fein­gold was Dai­ichi Sankyo’s VP of US med­ical af­fairs and chair­man of the Glob­al Med­ical Af­fairs Over­sight Com­mit­tee. With­in weeks in March, Pyx­is struck a li­cens­ing deal with Pfiz­er for two of its AD­Cs and raked in $152 mil­lion from a Se­ries B round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.